Glenmark Progresses Novel Pain Asset With Partnering In Mind

Glenmark is moving ahead with studies for its inhibitor of mPGES-1 amid cautious optimism. Pain management is, however, not a core thrust for the Indian firm and it hopes to out-license the potential first-in-class molecule at some stage.

SC1703_Chalkboard Strategy_1200x675
GLENMARK IS PROGRESSING ITS PAIN MOLECULE

With its orally bioavailable inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), Glenmark Pharmaceuticals Ltd. is advancing a novel therapeutic target in pain management, an area that has seen limited progress in recent times. However, pain is not a core focus for the Indian company.

The Mumbai-based firm has received the go-ahead from India’s Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category